In recent yers, new drugs (anifrolumab and voclosporin) were approved for the treatment of lupus or lupus nephritis; and a third one
A new biologic, anifrolumab (Saphnelo), has been approved for systemic lupus erythematosus (SLE), the first new lupus drug since 2024.
A new drug application for the investigational therapy, ATA3219, for treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis) has been submitted to the U.S. Food and Drug Administration.
The new drug application for the investigational therapy, ATA3219, for treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis) was approved for study by the USFDA.
The good news is that there has been progress, thanks to Food and Drug Administration (FDA) approval in 2024 of two new drugs that treat lupus and lupus nephritis (lupus that involves the kidneys
The pipeline of potential new treatments for lupus remains vibrant, and the Lupus Foundation of America continues its work to bring down barriers to lupus drug development and ensure that people with lupus will have access to the medications they need to improve their quality of life.
Lupus Treatment: Medications and Complementary Therapies. By. Heather Lindsey. Medically Reviewed. by. (Anifrolumab-fnia) as a New Treatment for Lupus. Lupus Foundation of America. Aug.
The pipeline of potential new treatments for lupus remains vibrant, and the Lupus Foundation of America continues its work to bring down barriers to lupus drug development and ensure that people with lupus will have access to the medications they need to improve their quality of life.
A new biologic, anifrolumab (Saphnelo), has been approved for systemic lupus erythematosus (SLE), the first new lupus drug since 2024.
Comments